EXTX — Exact Therapeutics AS Income Statement
0.000.00%
Last trade - 00:00
- NOK179.98m
- NOK142.30m
2018 December 31st | R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | NAS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.62 | 16 | 34.7 | 59.1 | 40.8 |
Operating Profit | -7.62 | -16 | -34.7 | -59.1 | -40.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.59 | -14.8 | -33.1 | -58.6 | -40.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.59 | -14.8 | -33.1 | -58.6 | -40.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.59 | -14.8 | -33.1 | -58.6 | -40.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.59 | -14.8 | -33.1 | -58.6 | -40.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.253 | -0.494 | -2.13 | -1.95 | -1.33 |
Dividends per Share |